Cancer drug’s survivin suppression called into question

Previous Post: nbsp

Cancer drug’s survivin suppression called into question

Nature – [The protein survivin] was named for its ability to promote cell survival in cancer by blocking programmed cell death—and it’s a protein that has become steadily more familiar in the cancer field in recent years. [Discovered] in 1997, survivin has emerged as one the most commonly found proteins in tumor cells. [It is rare] in healthy tissue, [so] you can understand why several companies have invested heavily in putative antisurvivin agents, with a handful already in clinical testing. The lead compound—YM155 from Japan’s Astellas Pharma—has already completed phase 2 trials for various forms of cancers. However, new data are emerging from preclinical tests to suggest that the drug might not be working exactly as first anticipated. Read article

Tags: , ,

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Powered by WordPress | Designed by: Premium WordPress Themes | Thanks to Themes Gallery, Bromoney and Wordpress Themes